Volume 8, Issue 2, March 2022

Optimizing individual heart failure treatment

• Extract
• View article

Efficacy and Safety of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER trial): a multicentre, randomized, double-blind, placebo-controlled trial

• Abstract
• View article
• Supplementary data

Different left ventricular remodelling patterns and clinical outcomes between non-ischaemic and ischaemic aetiologies in heart failure patients receiving sacubitril/valsartan treatment

• Abstract
• View article
• Supplementary data

Cardiac and cardiometabolic phenotyping of trastuzumab-mediated cardiotoxicity: a secondary analysis of the MANTICORE trial

• Abstract
• View article
• Supplementary data

β-blocker and 1-year outcomes among patients hospitalized for heart failure with mid-range ejection fraction

• Abstract
• View article
• Supplementary data

Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial

• Abstract
• View article
• Supplementary data

Effect of statin therapy on SARS-CoV-2 infection-related mortality in hospitalized patients

• Abstract
• View article
• Supplementary data

Renin–angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis

• Abstract
• View article
• Supplementary data

Long-term cardiovascular outcomes after orlistat therapy in patients with obesity: a nationwide, propensity-score matched cohort study

• Abstract
• View article
• Supplementary data

Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing

• Abstract
• View article

Corrigendum to: Treatment of Fabry Disease management with migalastat—outcome from a prospective 24 months observational multicenter study (FAMOUS)

• Extract
• View article